

25 July 2023

Our Ref: RFI 51482

Dear

**Freedom of Information Act 2000
Information in Relation to Biologic Medicines in Gastroenterology**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 07 June 2023. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Surgery & Elective, Maternity & Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Robyn Watterson
Information Governance Officer**

Q1. How many patients were treated in the last 3 month by the Gastroenterology Department (for any medical condition) with the following biologic drugs:

- **Adalimumab – Humira**
- **Adalimumab Biosimilar**
- **Filgotinib**
- **Golimumab**
- **Infliximab – Remicade**
- **Infliximab Biosimilar**
- **Ozanimod**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**
- **Vedolizumab Injections ONLY (pre-filled pens or syringes)**

A1. Please note the patient numbers supplied in A1 and A2 relate to all sites at the Trust from 01/03/23 to 31/05/23. Where numbers are 1-4, in line with Trust policy, it is given as <5 to reduce any risk of identification of individual patients.

Drug	Number of Patients
Adalimumab – Humira	10
Adalimumab Biosimilar	221
Filgotinib	7
Golimumab	<5
Infliximab – Remicade	<5
Infliximab Biosimilar	245
Ozanimod	<5
Tofacitinib	7
Upadacitinib	<5
Ustekinumab	154
Vedolizumab	69
Vedolizumab Injections ONLY (pre-filled pens or syringes)	29

Q2. If you are to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- **Adalimumab – Humira**
- **Adalimumab Biosimilar**
- **Filgotinib**
- **Golimumab**

- ***Infliximab – Remicade***
- ***Infliximab Biosimilar***
- ***Ozanimod***
- ***Tofacitinib***
- ***Upadacitinib***
- ***Ustekinumab***
- ***Vedolizumab***
- ***Vedolizumab Injections ONLY (pre-filled pens or syringes)***

A2. Please see table below. Where numbers 1-4 in line with Trust policy, it is given as <5, to reduce any risk of identification of individual patients.

Drug	Number of Patients
Adalimumab – Humira	<5
Adalimumab Biosimilar	64
Filgotinib	7
Golimumab	<5
Infliximab – Remicade	<5
Infliximab Biosimilar	88
Ozanimod	<5
Tofacitinib	7
Upadacitinib	<5
Ustekinumab	25
Vedolizumab	40
Vedolizumab Injections ONLY (pre-filled pens or syringes)	18